Impact of partial volume correction on the regional correspondence between in vivo [C-11]PiB PET and postmortem measures of Aβ load

[1]  Clifford R. Jack,et al.  Optimizing PiB-PET SUVR change-over-time measurement by a large-scale analysis of longitudinal reliability, plausibility, separability, and correlation with MMSE , 2017, NeuroImage.

[2]  Sang Won Seo,et al.  Regional correlations between [11C]PIB PET and post-mortem burden of amyloid-beta pathology in a diverse neuropathological cohort , 2016, NeuroImage: Clinical.

[3]  Keith A. Johnson,et al.  Partial volume correction in quantitative amyloid imaging , 2015, NeuroImage.

[4]  L. Ferrucci,et al.  Correspondence between in vivo 11C-PiB-PET amyloid imaging and postmortem, region-matched assessment of plaques , 2012, Acta Neuropathologica.

[5]  Clifford R. Jack,et al.  Ante mortem amyloid imaging and β-amyloid pathology in a case with dementia with Lewy bodies , 2012, Neurobiology of Aging.

[6]  O. Lopez,et al.  Early AD pathology in a [C-11]PiB-negative case: a PiB-amyloid imaging, biochemical, and immunohistochemical study , 2012, Acta Neuropathologica.

[7]  M. Modat,et al.  The importance of appropriate partial volume correction for PET quantification in Alzheimer’s disease , 2011, European Journal of Nuclear Medicine and Molecular Imaging.

[8]  Susan M Resnick,et al.  In vivo fibrillar beta-amyloid detected using [11C]PiB positron emission tomography and neuropathologic assessment in older adults. , 2011, Archives of neurology.

[9]  E. Salmon,et al.  18F‐flutemetamol amyloid imaging in Alzheimer disease and mild cognitive impairment: A phase 2 trial , 2010, Annals of neurology.

[10]  James Robert Brašić,et al.  In Vivo Imaging of Amyloid Deposition in Alzheimer Disease Using the Radioligand 18F-AV-45 (Flobetapir F 18) , 2010, Journal of Nuclear Medicine.

[11]  M. Weiner,et al.  Increased metabolic vulnerability in early-onset Alzheimer's disease is not related to amyloid burden. , 2010, Brain : a journal of neurology.

[12]  N. Cairns,et al.  In vivo amyloid imaging in autopsy-confirmed Parkinson disease with dementia , 2010, Neurology.

[13]  Mark A Mintun,et al.  Absence of Pittsburgh compound B detection of cerebral amyloid beta in a patient with clinical, cognitive, and cerebrospinal fluid markers of Alzheimer disease: a case report. , 2009, Archives of neurology.

[14]  Yu Kyeong Kim,et al.  Imaging of amyloid plaques and cerebral glucose metabolism in amnestic mild cognitive impairment , 2009, Alzheimer's & Dementia.

[15]  J. Mann,et al.  Voxel-Based Analysis of 11C-PIB Scans for Diagnosing Alzheimer's Disease , 2008, Journal of Nuclear Medicine.

[16]  S. DeKosky,et al.  Post-mortem correlates of in vivo PiB-PET amyloid imaging in a typical case of Alzheimer's disease , 2008, Brain : a journal of neurology.

[17]  C. Rowe,et al.  Imaging of amyloid β in Alzheimer's disease with 18F-BAY94-9172, a novel PET tracer: proof of mechanism , 2008, The Lancet Neurology.

[18]  Markus Schwaiger,et al.  Imaging of amyloid plaques and cerebral glucose metabolism in semantic dementia and Alzheimer’s disease , 2008, NeuroImage.

[19]  Keith A. Johnson,et al.  Molecular imaging with Pittsburgh Compound B confirmed at autopsy: a case report. , 2007, Archives of neurology.

[20]  S. DeKosky,et al.  Simplified quantification of Pittsburgh Compound B amyloid imaging PET studies: a comparative analysis. , 2005, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[21]  S. DeKosky,et al.  Kinetic Modeling of Amyloid Binding in Humans using PET Imaging and Pittsburgh Compound-B , 2005, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[22]  W. Klunk,et al.  Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound‐B , 2004, Annals of neurology.

[23]  W. Klunk,et al.  Synthesis and evaluation of 11C-labeled 6-substituted 2-arylbenzothiazoles as amyloid imaging agents. , 2003, Journal of medicinal chemistry.

[24]  Vincent Frouin,et al.  Correction of partial-volume effect for PET striatal imaging: fast implementation and study of robustness. , 2002, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[25]  A. Dale,et al.  Whole Brain Segmentation Automated Labeling of Neuroanatomical Structures in the Human Brain , 2002, Neuron.

[26]  Thomas E. Nichols,et al.  Comparative evaluation of MR-based partial-volume correction schemes for PET. , 1999, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[27]  A. Evans,et al.  Correction for partial volume effects in PET: principle and validation. , 1998, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[28]  Giovanni B. Frisoni,et al.  Consensus report of the working group on: 'Molecular and biochemical markers of Alzheimer's disease' , 1998 .

[29]  S. M. Sumi,et al.  The Consortium to Establish a Registry for Alzheimer's Disease (CERAD) , 1991, Neurology.

[30]  H. Mayberg,et al.  Correction of PET Data for Partial Volume Effects in Human Cerebral Cortex by MR Imaging , 1990, Journal of computer assisted tomography.

[31]  M. Folstein,et al.  Clinical diagnosis of Alzheimer's disease , 1984, Neurology.

[32]  J C Mazziotta,et al.  Quantitation in Positron Emission Computed Tomography: 5. Physical–Anatomical Effects , 1981, Journal of computer assisted tomography.

[33]  E. Hoffman,et al.  Quantitation in Positron Emission Computed Tomography: 1. Effect of Object Size , 1979, Journal of computer assisted tomography.

[34]  FDA approves 18F-florbetapir PET agent. , 2012, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[35]  J. Spillane,et al.  Positron emission tomography imaging and clinical progression in relation to molecular pathology in the first Pittsburgh Compound B positron emission tomography patient with Alzheimer's disease. , 2011, Brain : a journal of neurology.

[36]  Elin Wallstén,et al.  Correction for partial volume effects in PET imaging , 2011 .

[37]  Gopal B. Saha,et al.  Performance Characteristics of PET Scanners , 2010 .

[38]  Nikos Makris,et al.  Automatically parcellating the human cerebral cortex. , 2004, Cerebral cortex.

[39]  Hans Förstl,et al.  Clinical features of Alzheimer’s disease , 1999, European Archives of Psychiatry and Clinical Neuroscience.

[40]  Alan C. Evans,et al.  Pixel- versus Region-Based Partial Volume Correction in PET 1 1Transcripts of the BRAINPET97 discussion of this chapter can be found in Section VIII. , 1998 .

[41]  Nancy Reagan,et al.  Consensus Report of the Working Group on: "Molecular and Biochemical Markers of Alzheimer's Disease" , 1998 .